carbapenems has been researched along with gatifloxacin in 1 studies
| Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (gatifloxacin) | Trials (gatifloxacin) | Recent Studies (post-2010) (gatifloxacin) |
|---|---|---|---|---|---|
| 7,355 | 147 | 5,277 | 1,047 | 131 | 268 |
| Protein | Taxonomy | carbapenems (IC50) | gatifloxacin (IC50) |
|---|---|---|---|
| DNA gyrase subunit A | Escherichia coli K-12 | 0.5 | |
| DNA gyrase subunit B | Escherichia coli K-12 | 0.5 | |
| DNA topoisomerase 4 subunit A | Staphylococcus aureus | 1.2 | |
| DNA gyrase subunit A | Mycobacterium tuberculosis H37Rv | 9.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burgess, DS; Frei, CR; Moczygemba, LR | 1 |
1 other study(ies) available for carbapenems and gatifloxacin
| Article | Year |
|---|---|
Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Ciprofloxacin; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Klebsiella pneumoniae; Lactams; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Ofloxacin; Thienamycins | 2004 |